Sponsorship Statement: This continuing medical education activity is jointly sponsored by 
and 
Support Statement: This activity is supported by an educational grant from 
Target Audience: The intended audience for this activity is medical oncologists, surgical oncologists, hematologists/oncologists, oncology nurses, and other health care professionals involved in the treatment of patients with glioblastoma.
Learning Objectives:
After reviewing the material, the participants should be able to:
- Understand use of temozolomide in management of newly diagnosed glioblastoma.
- Describe the applicability of molecular studies in glioblastoma case management.
- Evaluate investigational treatments for glioblastoma and the clinical trials examining their efficacy and safety.
Faculty:
Marc C. Chamberlain, MD
Professor and Director of Medicine, Neuro-Oncology
University of Washington
Department of Neurology and Neurological Surgery
Fred Hutchinson Cancer Research Center
Seattle Cancer Care Alliance
Seattle, WA
David A. Reardon, MD
Clinical Director
Center for Neuro-Oncology
Dana-Farber Cancer Institute
Boston, MA
Accreditation:
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Vindico Medical Education and HemOnc Today®. Vindico Medical Education is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation:
Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release, July 10, 2012 to July 10, 2013.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the pretest questions, read the articles, complete the CME posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 70% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.
Planning Committee and Faculty:
Marc C. Chamberlain, MD
David A. Reardon, MD
External Reviewer:
Timothy Cloughesy, MD
Medical Writer:
Marykate Nelson, PhD (Vindico Medical Education Staff)
Valerie Anne Zimmerman, PhD
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Marc C. Chamberlain, MD
Consulting Fees:Genentech/Roche; Sigma Tau
Fees for Non-CME Services received directly from a commercial interest: Genentech
Contracted Research: Exelixis; MedImmune; Myriad; NCCN; Northwestern Genentech Study
David A. Reardon, MD
Consulting Fees: Abbott; Genontech/Roche; Schering/Merck
External Reviewer reports the following relationship(s):
Timothy Cloughesy, MD
Consulting Fees: Novartis, Merck Serono, Merck, Roche, Celgene, Genentech
Fees for Non-CME Services received directly from a commercial interest: Merck
Medical Writer reports the following relationship(s):
Valerie Anne Zimmerman, PhD
No relevant financial relationships to disclose
Vindico Medical Education and HemOnc Today® staff report the following relationship(s):
No relevant financial relationships to disclose
Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2012 SLACK Incorporated®. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education and HemOnc Today® continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education and HemOnc Today®. Neither Vindico Medical Education, HemOnc Today®, nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.